• Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system...
    18 KB (2,001 words) - 20:34, 1 December 2023
  • receiving both the 2 and 5 mg/kg doses. Leronlimab is a lab-made antibody that functions as an entry inhibitor. Leronlimab binds to the CCR5 receptor on the...
    50 KB (5,518 words) - 03:23, 5 December 2023
  • leronlimab (PRO 140), in combination with chemotherapy following strong results in animal murine models. Among other mechanisms of action, leronlimab...
    28 KB (3,411 words) - 03:40, 14 June 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    Lerdelimumab mab human TGF-β2 reduction of scarring after glaucoma surgery Leronlimab mab humanized CCR5 breast cancer, HIV Lesofavumab mab human Hemagglutinin...
    136 KB (4,020 words) - 07:14, 15 August 2024
  • Thumbnail for CCR5
    homing to the metastatic site. CCR5 inhibitors including maraviroc and leronlimab have been shown to block lung metastasis of human breast cancer cell lines...
    67 KB (7,852 words) - 18:22, 10 September 2024
  • Thumbnail for Cabotegravir/rilpivirine
    (Enfuvirtide (ENF, T-20))◊ CCR5 (Maraviroc (MVC) Vicriviroc†, Cenicriviroc†, Leronlimab†) CD4 (Ibalizumab (IBA), Semzuvolimab§) gp120 (Fostemsavir (FTR)) Integrase...
    15 KB (1,230 words) - 02:38, 16 July 2024
  • Thumbnail for AmfAR
    Vyrologix (Leronlimab) to mediate a functional HIV cure. According to Kevin Robert Frost, Chief Executive Officer at amfAR, "demonstrating that Leronlimab can...
    62 KB (6,911 words) - 16:58, 9 June 2024
  • Thumbnail for Dapivirine Ring
    (Enfuvirtide (ENF, T-20))◊ CCR5 (Maraviroc (MVC) Vicriviroc†, Cenicriviroc†, Leronlimab†) CD4 (Ibalizumab (IBA), Semzuvolimab§) gp120 (Fostemsavir (FTR)) Integrase...
    28 KB (2,975 words) - 02:18, 11 August 2024
  • HIV entry and the possibility that they may serve as entry inhibitors. Leronlimab, a monoclonal antibody that binds CCR5 Plerixafor was being developed...
    9 KB (1,095 words) - 03:47, 25 December 2023
  • Thumbnail for Richard Pestell
    the company's cancer clinical trial for the use of a CCR5 inhibitor (leronlimab) and FDA fast track designation in May 2019. He exited CytoDyn in July...
    30 KB (2,861 words) - 12:44, 28 August 2024
  • (Enfuvirtide (ENF, T-20))◊ CCR5 (Maraviroc (MVC) Vicriviroc†, Cenicriviroc†, Leronlimab†) CD4 (Ibalizumab (IBA), Semzuvolimab§) gp120 (Fostemsavir (FTR)) Integrase...
    3 KB (338 words) - 13:45, 27 July 2023